VIDEO: 90 Seconds With… Dr. Bill Ketelbey, Actinogen Medical
Got 90 seconds? Then listen to Actinogen Medical CEO and managing director Dr. Bill Ketelbey tell us about his AusBiotech Invest presentation and upcoming news-flow.
Actinogen Medical (ASX:ACW) is a biotechnology company focused on the development of innovative approaches for treating cognitive impairment associated with chronic neurological and metabolic diseases.
The company’s lead compound Xanamem, is a therapy under development for a number of conditions associated with cognitive impairment, including Alzheimer’s disease, a condition with multibillion-dollar market potential and material human impact.
In October Actinogen announced impressive efficacy results from XanaHES, its Phase I clinical trial assessing the safety and efficacy of 20mg Xanamem daily. The trial demonstrated a statistically significant cognitive improvement in the human trial subjects, a breakthrough result.
We caught up with Dr. Bill Ketelbey at the 2019 AusBiotech event and gave him 90 Seconds to tell us more about the company.
Have a good idea for our next 90 Seconds With segment? Email us at [email protected].